23 Jan

How Is Novartis’s Cosentyx Positioned for 2018?

WRITTEN BY Daniel Collins

Cosentyx revenue trends

In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) Cosentyx generated revenues of $410 million, $490 million, and $556 million, respectively. Cosentyx (secukinumab) is an IL-17A inhibitor indicated for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. Cosentyx is also used for the treatment of most hard-to-treat plaque psoriasis-palmoplantar psoriasis, nail psoriasis, and scalp psoriasis.

How Is Novartis’s Cosentyx Positioned for 2018?

Recent developments

In January 2018, Novartis presented the results of the head-to-head Clarity trial, which demonstrated the superiority of Cosentyx compared to Johnson & Johnson’s (JNJ) Stelara in promoting clear skin in adults with moderate-to-severe plaque psoriasis.

Novartis conducted the Clarity trial to evaluate whether Cosentyx (secukinumab) 300 mg is superior to Stelara (ustekinumab) for the treatment of moderate-to-severe plaque psoriasis.

In the Clarity trial, 66.5% and 72.3% of patients receiving Cosentyx, respectively, achieved co-primary endpoints PASI 90 (90% clearance in Psoriasis Area and Severity Index) and IGA mod 2011 0/1 (Investigator’s Global Assessment) compared to 47.9% and 55.4% of patients receiving Stelara.

The trial met all its key secondary endpoints. At week four, 40.2% of patients on Cosentyx achieved PASI 75 compared to 16.3% of patients receiving Stelara. Also, at week 16, 76.6% of patients receiving Cosentyx achieved PASI 75 compared to 79.8% of patients on Stelara.

Cosentyx competes with Eli Lilly’s (LLY) Taltz, Celgene’s (CELG) Otezla, Amgen’s (AMGN) Enbrel, and AbbVie’s Humira.

The growth in sales of Novartis’s Cosentyx could boost the Vanguard FTSE All-World ex-US ETF (VEU). Novartis makes up about ~0.92% of VEU’s total portfolio holdings.

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

14 Jun

Why Kimberly-Clark Stock May Stop Rising

WRITTEN BY Amit Singh

Kimberly-Clark (KMB) stock has risen 20.5% this year, boosted by the company’s better-than-expected sales and earnings during its last reported quarter. However, its stock could stop climbing. Here's why.

172.31.38.64